Celebrex Malpractice Claim

Celebrex Malpractice Claim

Pfizer Incorporation manufacturer of Celebrex is most widely prescribed for arthritis pain. The Company reaped a rewarding profit of $3 billion dollars in sale of Celebrex. It belongs to the class of pain killers known as “Cox-2 inhibitors,”. The Cox-2 inhibitors are three in total. Vioxx was withdrawn from the market on September 30, 2004 as it led to heart attacks and strokes. In December 2004, Bextra, the third Cox-2 inhibitor also manufactured by Pfizer carried a warning label displaying probable heart problems associated with it.

A study of Celebrex showed that the patients taking medication daily had twice the increase in risk shown by Vioxx studies and so Celebrex study was stopped. FDA has suggested that non-steroidal anti-inflammatory drugs (NSAIDs) comprise a warning to emphasize the risk of cardiovascular damage and life threatening, gastrointestinal bleeding and also to include an indication to avoid usage in patients immediately after coronary artery bypass surgery.

Celebrex lessen indication of osteoarthritis, rheumatoid arthritis in adults, control sharp pain in adults due to dental and surgical operations, and take care of painful menstrual cycles.

FDA committees conducted a three days meeting to assess the risk of the 3 Cox-2 inhibitors, in which Celebrex was collectively chosen to cause high risk of heart problems. But later it was decided to let it stay in market as its benefit exceeded its dangers.

Instead of preventing the number of deaths due to these drugs, the law is shielding the pharmaceutical giants who are responsible for these deaths by arranging a compensation amount for the victim’s family.